Hillenbrand (NYSE: HI), Milacron’s current owner, will continue to remain a significant investor in the business. BOSTON & BATESVILLE, Ind.--(BUSINESS WIRE)--Bain Capital, a leading private investment ...

Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...

According to the terms of the deal, Bain has agreed to acquire a 51 percent stake in Milacron for $287 million.

On February 5, the company entered into a definitive agreement to sell an ownership stake of approximately 51% in its Milacron injection ...

Taking a look at a Graham Partners-backed technology company that is pursuing a continuation vehicle funding after running a ...

Key alts deals unveiled today include Silver Point's $250 million CLO fund close, Bain Capital's stake in manufacturer Milacron, a KKR-backed tech acquisition.

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Keith Largay joins Bain Capital from JLL, where he spent 14 years and most recently served as co-head of its Chicago office.

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...

The provider of highly-engineered processing equipment and solutions will sell a 51% stake in the injection molding and extrusion business for $287 million.